Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEI Trial: Hypofractionated Chemoradiotherapy for Esophageal Cancer
jRCT1030250515Phase 2Recruiting
- Start
- Nov 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in esophageal cancer, sponsored by None. Primary endpoint: Two-year progression-free survival. Started Nov 2025; status: recruiting.
02
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1030250515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030250515.